• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 20th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Tom Little
Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Tom Little
Home
Business
Healthcare & Pharmaceuticals

UK online pharmacy Rightangled still selling diabetes drug Ozempic despite govt order

October 20th, 2023 | 14:11 PM BUSINESS Healthcare & Pharmaceuticals 3

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

First screwworm case detected in Mexican state of Sonora
Multistate salmonella infections climb to 431, US CDC says
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder
Michigan confirms human case of rare mosquito-borne disease
By Maggie Fick

UK private online pharmacy Rightangled was offering Novo Nordisk's diabetes drug Ozempic for sale on Friday to people wanting to use the weekly injection to shed pounds, its website shows, even after a government order to stop doing so.

Ozempic is licensed in the UK for managing blood sugar levels in people with type 2 diabetes. However, last year, many people who don't have diabetes turned to Ozempic as a slimming jab, using online pharmacies prescribing it “off-label”.

In July, the Department of Health and Social Care (DHSC) and Britain's National Health Service declared a national shortage of Ozempic and all other drugs in a class called "GLP-1 receptor agonists" due to the soaring demand for approved and off-label use.

It warned the shortage will last until at least mid-2024.

It also instructed doctors and other prescribers, like private online pharmacies, to stop prescribing Ozempic to people who don't have type 2 diabetes as soon as possible and not later than Oct. 18. It also banned prescribers from starting new patients with type 2 diabetes on the medicine for as long as the shortage lasts.

The Rightangled offers to ship the drug were displayed on the pharmacy's website on Friday under its "general health: weight loss" section noting it was for "diabetes management but can aid in weight loss as off label."

Rightangled, a UK-based online pharmacy chain, and DHSC did not immediately respond to requests for comment.

On Thursday, Rightangled, a privately owned and UK-registered pharmacy that delivers prescription medicines to customers that place online orders, offered to supply Ozempic to one of its customers in an email reviewed by Reuters.

"Grab yours before it's gone again," the email which was dated Oct. 19 and shared with Reuters by the customer says, including a photograph of an Ozempic pen in a box.

Reuters on Friday checked the websites of other private online pharmacies that have prescribed Ozempic this year for weight-loss.

One of them, Farmeci, lists only Wegovy and Saxenda, another Novo Nordisk medicine that like Wegovy is approved for weight-loss, under its weight-loss treatments section.

Another, Juniper, a venture capital-backed private online clinic, refers on its site to Ozempic as a medicine “licensed to treat diabetes in the UK”.

A third, Simple Online Pharmacy, mentions this in its description of Ozempic: “Because Ozempic is primarily a drug used in diabetes, we choose not to prescribe this, so as not to affect critical supply chains for diabetic patients.”

  • Topic
  • HEALTH
  • OBESITY/OZEMPIC (PIX)
Facebook Twitter Google+ LinkedIn Pinterest
Previous article First screwworm case detected in Mexican state of Sonora

Related Posts

Healthcare & Pharmaceuticals
August 20th, 2026

First screwworm case detected in Mexican state of Sonora

Healthcare & Pharmaceuticals
August 19th, 2026

Multistate salmonella infections climb to 431, US CDC says

Healthcare & Pharmaceuticals
August 19th, 2026

Ultragenyx's gene therapy wins first FDA approval for rare metabolic dis...

Healthcare & Pharmaceuticals
August 19th, 2026

Michigan confirms human case of rare mosquito-borne disease

Healthcare & Pharmaceuticals
August 19th, 2026

US FDA approves Regeneron's rare bone disorder drug

Healthcare & Pharmaceuticals
August 19th, 2026

West Nile virus outbreak kills four in North Macedonia 

The Wire
Aug 20th 2 h ago
Technology

China puts robocops on traffic duty, minus the arrest power...

Aug 20th 2 h ago
Soccer

Japan's Miura, 59, becomes oldest scorer in Emperor's Cup h...

Aug 20th 2 h ago
Environment

A decade after earthquake, Italy's Amatrice struggles to re...

Aug 20th 2 h ago
ROI: Reuters Open Interest

The Iran war energy crisis is just getting started

Aug 20th 2 h ago
Media & Telecom

'Baby Shark' boy returns to stage as a K-pop singer

TRENDING ON FINANCETIME
Aug 20th, 2026 Litigation

SK Hynix to pay 60% of employee bonuses in company stock under preliminary deal, says source

Aug 20th, 2026 Asia Pacific

Outsider who could decide New Zealand's next government wants to tax wealth, not work

Aug 20th, 2026 Business

Aegon raises share buyback plan to 350 million euros

Aug 20th, 2026 Africa

South Africa's Exxaro half-year profit down 20%, cuts dividend

Aug 20th, 2026 Cricket

Australia look for response to 'Darwin Disaster' in second Bangladesh test

Markets-Sectors
BASIC MATERIALS +1.43%
UTILITIES +0.00%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT